Severe Community-Acquired Pneumonia due to Acinetobacter baumannii in North America: Case Report and Review of the Literature

Serota, David P.; Sexton, Mary Elizabeth; Kraft, Colleen S.; Palacio, Federico

doi:10.1093/ofid/ofy044

Cited by 35 publications

(36 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CAP cases caused by A. baumannii are very rare in Europe and USA. A recent USA case report of severe CAP and review of the literature found that 19 cases of CAP caused by A. baumannii have been reported in the USA to date [26].…”

Section: Cap Caused By Acinetobacter Baumaniimentioning

confidence: 99%

Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia

2019

View full text Add to dashboard Cite

This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2019. Other selected articles can be found online at https://www.biomedcentral.com/collections/annualupdate2019 . Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://www.springer.com/series/8901 .

show abstract

Section: Cap Caused By Acinetobacter Baumaniimentioning

confidence: 99%

Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia

2019

View full text Add to dashboard Cite

show abstract

“…In Europe and North America, however, A. baumannii is exceedingly rare. A recent USA report found that only 19 cases of severe CAP were caused by this pathogen [24]. Interestingly, in a case-control study in the USA that aimed to characterize the epidemiology of MDR A. baumannii colonization in high-risk nursing home residents, 15% (n = 25) of residents were noted to be colonized, with all isolates being resistant to cephalosporins, monobactam (aztreonam), and quinolones.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Emerging antibiotics for community-acquired pneumonia

Liapikou

Cillóniz

Palomeque

et al. 2019

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Introduction: Community-acquired pneumonia is the most common infection leading to hospitalization and death in all age groups, especially in elderly populations. Increasing antibiotic resistance among the common bacterial pathogens associated with community-acquired pneumonia, especially Streptococcus pneumoniae and staphylococci, has made its empirical treatment increasingly problematic, highlighting the need for effective antibiotic therapy. Areas covered: We searched PubMed and ClinicalTrials.gov for English-language reports of phase III clinical trials conducted between 2000 and 2019 concerning the antibiotic treatment of community-acquired pneumonia. We provide a summary of the latest approved drugs for this indication and highlight emerging drugs with a potential indication. Expert opinion: Ceftaroline (a new cephalosporine) and omadacycline (a cycline alternative), either parenterally or orally, are the only two new antibiotics to have been approved by the FDA for the treatment of community-acquired pneumonia in the last five years. Among the antimicrobials in development, Lefamulin (the first pleuromutilin), is currently in phase III development. Among the known antibiotic classes, solithromycin (a macrolide), nemonoxacin (a quinolone), and delafloxacin and zabofloxacin (both fluoroquinolones), have been studied in phase II and III in clinical trials. The availability of these new antibiotics may offer opportunities to improve the empirical treatment for community-acquired pneumonia.

show abstract

“…Acinetobacter baumannii associated CAP has been reported from countries in tropical or subtropical regions such as Australasia, Asia and Middle East [ 2 , 6 ]. Despite higher incidence in warm climate countries, there have been reported cases in North America as well [ 7 ]. Acinetobacter baumannii is one of the three recognized organisms that can cause severe MDR community acquired pneumonia in addition to Streptococcus pneumoniae and methicillin resistant Staphylococcus aureus [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Community acquired multi drug resistant (MDR) Acinetobacter baumannii pneumonia in Malaysia – A case report

Mohd

Nesam

Kamaruzaman

et al. 2018

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Acinetobacter baumannii is an aerobic Gram-negative coccobacillus that is associated with hospital acquired pneumonia. There is increased reporting of emergent cases of community acquired multidrug resistance (MDR) acinetobacter associated with a higher mortality due to antibiotic resistance. Community acquired MDR acinetobacter pneumonia has not been reported in Malaysia. Here we report a case of a 19-year-old army officer who presented with fever and respiratory symptoms for 5 days. He had no known medical illness before and no history of hospitalization. Upon arrival, he was in septicaemic shock, requiring invasive ventilator support and renal replacement therapy in intensive care unit. Chest radiograph showed bilateral lung consolidations and bronchoscopy revealed haemoserous and greenish bronchiole secretion. He was treated with broad spectrum antibiotics and oseltamivir. Unfortunately he died on day 3 of hospital admission. His bronchial lavage culture came back positive for MDR Acinetobacter baumannii. This case illustrates that clinicians need to be aware that MDR Acinetobacter baumannii can cause severe community acquired pneumonia. We may need to consider this diagnosis in patients who do not respond to standard therapy.

show abstract

Severe Community-Acquired Pneumonia due to Acinetobacter baumannii in North America: Case Report and Review of the Literature

Cited by 35 publications

References 22 publications

Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia

Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia

Emerging antibiotics for community-acquired pneumonia

Community acquired multi drug resistant (MDR) Acinetobacter baumannii pneumonia in Malaysia – A case report

Contact Info

Product

Resources

About